News Highlights

 

2011 FDA authorized JN's IND for conducting Conjugated Meningococcal vaccine human trials in Hanford, California

 

2011 Neurology scientists bags Stroke Grant Award - US Govt.

 

2006-2011 Meningitis vaccine for Disease outbreaks in India & sub-Saharan

 

CONFERENCES

 

Mr. Hankins & Dr.Reddy at NG Pharma conf in Amsterdam

 

Dr. Orten & Dr. Reddy - presentation at CNS World Summit in San Francisco

 

 
 

 

The corporation 

JNI Medical Corp - Admin Building
 

Do you Know? JN is the 3rd BioPharma, developed patented Meningococcal meningitis serogroups A/C/Y/W135 diphtheria toxoid conjugate vaccine (NmVac-4dt) which is now human phase. JN also developing vaccine for Genital Herpes and therapeutic Ischemic Stroke. Inc5000 Fastest Growing Company

 

 

Meningococcal VACCINE Meningococcal meningitis vaccine for children
 

Our Product & Products “NmVac-4dt is among the most complex biotech or biologic products. It’s a combination vaccine that contains four 4 different vaccines in one and can be used with any combination by the geographic prevalence of the disease causing serogroup.”

 

 

Flag of the United States.svg    American Exports

 

To Saharan Africa, Middle East, Latin America and Asia through our subsidiaries and distributions. Export product:

 

VaccinesDiagnostics

 

Neurological THERAPIES

 

Research JN neurology team has developed Biomarkers and Therapeutics to intervene TIA / Stroke, Epilepsy, Alzheimer's.

  1. Vaccine saves mice

  2. Auto Antibodies NEWS

  3. Biomarkers

  4. Stroke therapeutic

GLOBAL HEALTH

 

Filled Commitment

 

 

 

US President Malaria Initiative & JN International Medical Corporation